ETO2 coordinates cellular proliferation and differentiation during erythropoiesis
Abstract
The passage from proliferation to terminal differentiation is critical for normal development and is often perturbed in malignancies. To define the molecular mechanisms that govern this process during erythropoiesis, we have used tagging/proteomics approaches and characterized protein complexes nucleated by TAL-1/SCL, a basic helix–loop–helix transcription factor that specifies the erythrocytic lineage. In addition to known TAL-1 partners, GATA-1, E2A, HEB, LMO2 and Ldb1, we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21, encoding two essential regulators of erythroid cell proliferation. These results suggest that the dynamics of ETO2 recruitment within nuclear complexes couple cell proliferation to cell differentiation and determine the onset of terminal erythroid maturation.
Acknowledgments
We thank Drs Daniele Mathieu and Catherine Porcher for human or mouse TAL-1 antibodies, Dr Jeroen Krijgsveld for mass spectrometry analysis, B Izac for help in the preparation of the lentiviruses, R Lahlil for help with the VSV, MA Vinit, A Haman and A Perreault for technical help and Daniele Gagné for cell sorting. We thank all our colleagues for thoughtful discussions. NG was supported by studentships from the ARC and the French Hematology Society and JAL studentships from the National Science and Engineering Research Council, the Fonds de Recherche en Santé du Québec and the Canadian Institutes for Health Research (CIHR). This work was supported by grants from INSERM, CNRS, ARC, CIHR, the Cancer Research Society Inc. and the National Cancer Institute of Canada.